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Background: Therapeutic intervention in the pathophysiology of airway mucus hypersecretion is clinically
important. Several types of drugs are available with different possible modes of action. We examined the effects of
guaifenesin (GGE), N-acetylcysteine (NAC) and ambroxol (Amb) on differentiated human airway epithelial cells
stimulated with IL-13 to produce additional MUC5AC.
Methods: After IL-13 pre-treatment (3 days), the cultures were treated with GGE, NAC or Amb (10–300 μM) in the
continued presence of IL-13. Cellular and secreted MUC5AC, mucociliary transport rates (MTR), mucus rheology at
several time points, and the antioxidant capacity of the drugs were assessed.
Results: IL-13 increased MUC5AC content (~25%) and secretion (~2-fold) and decreased MTR, but only slightly
affected the G’ (elastic) or G” (viscous) moduli of the secretions. GGE significantly inhibited MUC5AC secretion and
content in the IL-13-treated cells in a concentration-dependent manner (IC50s at 24 hr ~100 and 150 μM,
respectively). NAC or Amb were less effective. All drugs increased MTR and decreased G’ and G” relative to IL-13
alone. Cell viability was not affected and only NAC exhibited antioxidant capacity.
Conclusions: Thus, GGE effectively reduces cellular content and secretion of MUC5AC, increases MTR, and alters
mucus rheology, and may therefore be useful in treating airway mucus hypersecretion and mucostasis in airway
diseases.
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Mucus in the airways is required to trap pathogens and
inhaled particles for clearance via the mucociliary escal-
ator towards the pharynx [1,2], where it and its trapped
particles are either swallowed or expectorated. Exposure
to irritants and pathogens causes leucocyte activation
and inflammatory mediator release, which increase
mucus production and enhance clearance of the inciting
stimuli. However, the balance between mucus produc-
tion and clearance [1] depends on optimal mucus quan-
tities and hydration state, and periciliary fluid depth [3].* Correspondence: jseagrav@LRRI.org
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reproduction in any medium, provided the orAirway bacterial or viral infections, asthma or chronic
bronchitis can cause excessive mucus production and se-
cretion. Combined with possible rheological changes,
altered ciliary beating or uncoupling from the ciliary
movement due to changes in liquid layer depth, these
conditions can cause defective mucociliary clearance and
airway mucus accumulation [1,4]. These factors lead, in
turn, to coughing and subjective discomfort. In extreme
cases, such as uncontrolled asthma, complete blockage
of the airways with mucus can occur. There is, therefore,
a need for improved therapeutic agents to improve
mucociliary function under these pathophysiological
conditions.
The major gel-forming mucins secreted by goblet cells
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MUC5AC is considered a biomarker for airway goblet
cells [7] and is widely used for studying goblet cell meta-
plasia in vivo and in vitro.
Pharmacological approaches for relieving mucus
hypersecretion currently include several classes of agents
[1]. Classic mucolytic drugs such as N-acetylcysteine
(NAC) decrease the viscoelastic properties of mucus by
reducing disulfide bonds. In contrast, expectorants
change mucus consistency and make coughing more
productive, mucokinetics improve transportability, and
mucoregulators suppress mucus secretion.
We previously investigated the effects of guaifenesin ([3-
(2-methoxyphenoxy)-1,2-propanediol], also called glyceryl
guaiacolate ether, GGE) in vitro, using primary human air-
way epithelial cells differentiated by air-liquid interface
culture [8]. These cultures are a complex, organotypic
human airway model, containing the major cell types:
basal, ciliated, non-ciliated and goblet cells [9]. Using this
system, we demonstrated that GGE reduced the cellular
content and secretion of MUC5AC, altered the viscoelas-
tic properties of the secretions, and improved mucociliary
transport rates (MTR) [8]. Here, we extend these observa-
tions to conditions in which MUC5AC secretion was
increased by culturing with IL-13 for 3 days prior to ana-
lysis [10]. We compared the effects of the expectorant,
GGE, with a mucolytic (NAC), and another mucoactive/
expectorant agent, ambroxol (Amb), a drug reported to
have anti-inflammatory, antioxidant and anaesthetic
effects [11]. Previous studies have suggested that IL-13
stimulation increases MUC5AC production (but not
MUC5B) [12]. We hypothesised that these drugs would
affect MUC5AC content and secretion and improve




Trolox equivalent antioxidant capacity was measured es-
sentially as previously described [13]. Dilutions of the
mucoactive agents and Trolox, a water-soluble vitamin E
analogue used as a standard, were prepared in Dulbecco’s
phosphate-buffered saline (DPBS), previously sparged with
nitrogen, and incubated with previously heated 0.23mM
2,2'-azinobis-(-3 ethylbenzothiazoline-6-sulphonate)/2.3 mM
2,2'-azobis-(-2-amidinopropane). The optical density
(734 nm) was read using a VersaMax (Molecular Devices,
Inc., Sunnyvale, CA USA) plate reader 5 minutes after ini-
tiating the reaction.
Cell cultures and exposures
Cultures of primary human airway epithelial cells, differ-
entiated at air-liquid interface for 2 weeks on 1 cm2 trans-
wells for the MUC5AC content and secretion assays or on4.2 cm2 transwells for the mucociliary transport and rhe-
ology assays (EpiAirway), were purchased from MatTek
(Ashland, MA, USA) and maintained according to the
supplier’s recommendations. A single donor was used for
all experiments. Except where noted, IL-13 (Lab Vision,
Thermo Fisher Scientific Inc., Kalamazoo, MI, USA) was
added at 1 ng/mL to the basolateral compartment for
3 days, replaced daily, prior to treatment with the mu-
coactive agents: GGE (provided by Reckitt Benckiser,
Parsippany, NJ, USA), NAC or Amb (Sigma-Aldrich, St.
Louis, MO, USA) [10]. For assessment of MUC5AC con-
tent and secretion, the apical surfaces were washed twice
with DPBS immediately before treatment with the mucoac-
tive agents. To ensure that sufficient mucus was present
for the analysis of mucociliary transport and mucus rheo-
logy, cultures for these experiments were washed 24 hr be-
fore treatment. The mucoactive agents, diluted to 10, 30,
100 and 300 μM in culture medium containing 1 ng/mL
IL-13 were provided basolaterally. Cultures treated with
IL-13 alone served as the “no drug” control, and an addi-
tional set received neither IL-13 nor drug. Each endpoint
evaluated the responses from a set of individual cultures:
the number of cultures is reported for each assay.
Cell viability and cellular levels and release of MUC5AC
For each analysis time point, quadruplicate cultures were
treated as described above. At the designated times, the
apical surfaces were gently washed twice with 100 μL of
DPBS containing 0.1 mM dithiothreitol (DTT). The
washes were centrifuged and the supernatants were frozen
for subsequent ELISA analysis of MUC5AC content. Via-
bility was assessed using the Water Soluble Tetrazolium
(WST-1) assay (Roche Applied Science, Indianapolis, IN,
USA). The cells were then lysed with 200 μL of 1% Triton
X-100, 2 mM EDTA and 10 μM Pefabloc (Roche Applied
Science) in DPBS. Following centrifugation, the superna-
tants were frozen for subsequent ELISA analysis.
MUC5AC ELISA
The ELISA followed previously described procedures [8],
using anti-MUC5AC antibody (45M1; Thermo Fisher),
peroxidase-conjugated secondary antibody, and high-
sensitivity tetramethylbenzidine development (Thermo
Fisher). The washes were diluted 1:4 and the lysates
were diluted 1:10 in DPBS for analysis. Standards con-
sisting of a pooled sample of EpiAirway secretions were
prepared in DPBS with 0.025 mM DTT for analysis of
the secreted MUC5AC, and in DPBS without DTT for
analysis of the lysate MUC5AC content, to account for
the non-linear relationship between concentration and
signal intensity and differences in antibody binding in
the presence of low levels of DTT. The standard curve
was fit to a 4-parameter regression, and the samples
were within the mid-range of this curve. The data are
Figure 1 Examples of “individual particles” or “mucus sheets”. The video files were processed using CISMM software (http://cismm.cs.unc.
edu/downloads/?dl_cat=3) to remove the invariant background, thus emphasizing the moving material, and every tenth frame is shown. Panel A
shows an example of a “single particle,” indicated by a circle, although a second particle is present. Panel B shows an example of a “mucus sheet”
where many elements are present, three of which are indicated as a circle, a square, and a triangle, that move together.
Figure 2 Antioxidant capacity of guaifenesin (GGE), N-
acetylcysteine (NAC) and ambroxol (Amb). The ability of the
three mucoactive agents to scavenge the free radical/colorimetric
indicator as a function of concentration was compared with Trolox
(a water soluble vitamin E analogue). NAC was approximately twice
as effective (slope -0.316) as Trolox (slope -0.155), but the effects of
GGE and Amb were minimal (slopes of 0.032 and 0.025,
respectively).
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pooled sample. None of the mucoactive agents interfered
with the assay.
Mucociliary transport
A separate set of EpiAirway cultures, similarly pre-treated
with IL-13, were treated in sextuplicate with the mucoac-
tive agents at either 30 or 100 μM. After 3, 8 or 24 hr,
videomicroscopy data were collected. In most cases, three
fields, selected on the basis of containing endogenous
moving material, were imaged for each of four cultures.
Post-imaging processing to assess the rate of movement of
endogenous debris on the surface of the cultures was per-
formed from the video, attempting to track at least five
particles for each microscopic field. In some cases there
was insufficient material to meet these targets. The images
were subjectively classified as “individual particles” or
“mucus sheets”, where mucus sheets were considered to
be larger masses of material moving synchronously across
the field. Examples are provided in Figure 1. After the 8-hr
time point, undiluted apical secretions were harvested
from 2 cultures per exposure condition and frozen for
subsequent micro-parallel plate rheology. The apical
secretions were similarly collected from the remaining
four cultures after the 24-hr imaging.
Rheology
The rheological properties of the mucus samples harvested
from the cell cultures were ascertained by performing
amplitude sweep experiments on a Bohlin Gemini Rhe-
ometer (Malvern Instruments, Worcestershire, UK), with
a 20 mm diameter parallel plate set at a gap thickness
of 50 μm. All experiments were performed over a stress
range of 0.025–50 Pa and at a frequency of 1 Hz(intermediate frequency between those associated with
tidal breathing and mucociliary clearance). All analyses
were performed at 23°C to minimise sample dehydra-
tion [14]. For each sample, we report data from the lin-
ear regimes, established through methods similar to
those of Vasquez et al. [15].
Statistical analysis
Statistical analysis of the effects of the test materials
on viability and mucus secretion and production were
Figure 3 Effects of guaifenesin (GGE), N-acetylcysteine (NAC)
and ambroxol (Amb) on cell viability. Viability after 3, 8 or 24 hr
of incubation with the concentrations of the drugs as indicated was
assessed using the Water Soluble Tetrazolium (WST-1) assay. The
horizontal line indicates the p-value for a statistically significant
trend for ambroxol at 24 hr, when the IL-13-only cultures were
included as the zero drug concentration as indicated by a short line
over the IL-13-only bar at the same height. (The trend test does not
include the comparator negative control culture, which was not
treated with IL-13).
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paring all samples against the IL-13-only control sample
at each time using GraphPad Prism software (version
5.04). In addition, a trend test evaluating the effect of
each drug as a function of concentration, including the
IL-13-only cultures as the zero drug concentration, was
performed. The effective concentration for 50% inhi-
bition (IC50) of the cellular MUC5AC content and secre-




NAC is known to alter mucus viscosity by reducing the
intramolecular disulphide bridges. We therefore investi-
gated whether either of the other agents had redox-
active properties. NAC had approximately twice the
antioxidant capacity of Trolox, with a slope of -0.316 vs.
-0.155 (Figure 2). Neither GGE nor Amb had any evi-
dent antioxidant capacity, with slopes of 0.032 and
0.025, respectively.
Viability
It is possible that a decrease in secretion or altered
mucociliary transport could result from toxicity of the
drugs tested. In order to confirm the lack of toxicity, we
assessed viability of the cells using the WST assay. None
of the experimental interventions significantly altered
cell viability at any time point studied based on the
ANOVA analysis comparing all individual data to the
IL-13-alone control (Figure 3). However, there was a
weak, but statistically significant trend, for Amb at the
24 hr time point.
MUC5AC secretion and content
Based on our previous evidence that GGE affected
MUC5AC production and secretion, we examined the
effects of all three drugs on this parameter in the IL-13-
stimulated cells. IL-13 pre-treatment increased MUC5AC
secretion in the pooled washes 2-fold (Figure 4) and cellu-
lar content by 25% (Figure 5). GGE significantly inhibited
IL-13-induced MUC5AC secretion in a concentration-
dependent manner at 3, 8 and 24 hr, with IC50 values (95%
confidence intervals, CI) of 137 (73–102), 130 (98–190)
Figure 4 Effect of guaifenesin (GGE), N-acetylcysteine (NAC) or
ambroxol (Amb) on secretion of MUC5AC. The MUC5AC
concentrations in two washes of the apical surfaces of quadruplicate
cultures for each condition were analysed by ELISA. All samples and
standards included 0.025 mM dithiothreitol (DTT), resulting from the
1:4 dilution of the samples collected in 0.1 mM DTT. The results from
the two washes were combined and are reported as the
concentration relative to the standard curve, generated from
dilutions of a pooled sample of washes collected from other
samples. Separate cultures were analysed at the three time points. *,
** and *** indicate p < 0.05, 0.01 and 0.005, respectively, vs. IL-13-
only group (ANOVA with Dunnett’s post-test). Horizontal lines above
the groups indicate significant trend tests (all include the IL-13-only,
zero drug, condition as indicated by the short line over this bar at
the same height).
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hr, 300 μM GGE reduced secretion below the levels of
non-IL-13-treated cells, consistent with our previous
observations [8]. NAC and Amb both significantly
reduced the levels of the secreted MUC5AC for some con-
centrations. However, the effect was not consistently
concentration-dependent and no clear pattern was
observed. Inhibition by 300 μM Amb or NAC was much
less than at the same concentration of GGE.
Similar to the effects on secretion, GGE decreased
the cellular content of MUC5AC in IL-13-treated
cultures at all time points, with an IC50 value at 24 hr
of 150 (95% CI: 95–330) μM (Figure 5); the cellular
content of MUC5AC in 300 μM GGE-treated cultures
was less than that in the non-IL-13-treated cells. Amb
and NAC also decreased the cellular content of
MUC5AC in IL-13-treated cultures at 3 and 8 hr, but
not at 24 hr (Figure 5). The inhibition at 3 and 8 hr was
not obviously concentration-dependent.
Mucociliary transport
A key factor in the clearance of mucus from the airways
is MTR. We examined the effects of IL-13 and the
effects of the drugs on MTR in the IL-13 stimulated
cells. Figure 1 shows examples of processed video files of
“individual particles” or “mucus sheets”. IL-13 reduced
MTR for combined particles+mucus sheets (denoted
“all” in the figure), and for mucus sheets alone, signifi-
cant for all except the 3hr combined samples (Figure 6).
The effects at 3, 8 and 24 hr for mucus sheets were 80,
75 and 89% reductions, respectively. These decreases in
MTR over the 24 hr observation period followed 3 days
of preincubation with IL-13.
At the 3 hr time point, none of the drugs had any sig-
nificant effect on the IL-13-induced reduction in MTR
(Figure 6); this was associated with marked variability in
response in some groups (e.g. 30 μM NAC, individual
particles). By 8 hr, MTR was 40 and 66% greater in cul-
tures treated with 30 and 100 μM GGE, respectively,
Figure 5 Effect of guaifenesin (GGE), N-acetylcysteine (NAC) or
ambroxol (Amb) on cellular MUC5AC content. The MUC5AC
content in lysates of quadruplicate cultures for each condition were
analysed by ELISA. No dithiothreitol was used in this ELISA because
the lysis buffer did not contain this reducing agent. The results are
reported as concentration relative to the standard curve, generated
from dilutions of a pooled sample of washes collected from other
samples. Separate cultures were analysed at the three time points. *,
** and *** indicate p < 0.05, 0.01 and 0.005, respectively, vs. the IL-
13-only group (ANOVA with Dunnett’s post-test). Horizontal lines
above the groups indicate significant trend tests (all include the IL-
13-alone, zero drug, condition as indicated by the short line over
this bar at the same height).
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100 μM, and with a marked biphasic effect on individual
particles. The lack of effect of 30 μM GGE on “all” MTR
was associated with the absence of mucus sheets in this
group. There was also a > 2-fold increase in MTR in cul-
tures treated with 30 μM NAC, driven by a marked ef-
fect on elements within sheets. At 100 μM NAC, there
was also a 2-fold increase in rate for individual particles,
but a decrease for those present in the mucus sheets.
Neither concentration of 100 μM Amb significantly
altered MTR, although there was a weak trend towards
an increase. At 24 hr, 30 μM GGE increased MTR of the
combined material over 6-fold relative to the IL-13-only,
~4-fold for individual particles and ~7-fold for mucus
sheets (Figure 6). The effect of 100 μM GGE (3-fold in-
crease) was only significant for the combined data. NAC
at 30 μM significantly increased MTR (2-fold) for both
individual particles and mucus sheets at 24 hr. In con-
trast, for cultures treated for 24 hr with 100 μM NAC
(Figure 6), only one field with any particles was found in
four cultures examined, and this field had a mucus sheet
with very low mobility. Amb at 30 and 100 μM signifi-
cantly increased MTR for combined material (~2.5-fold)
and sheets (~3.5- and ~2.5-fold), respectively, but the
effects on individual particles (40 and 60% increases)
were not significant. Multivariate analysis indicated sig-
nificant increases in MTR at 100 μM GGE and both
concentrations of NAC relative to the IL-13 group, irre-
spective of time or particle type. The effects of Amb
were not significant. There were also significant effects
of particle type, irrespective of time or treatment: parti-
cles within mucus sheets had lower MTR than individual
particles.
Rheology
Increases in mucus viscosity and elasticity contribute to
mucostasis and its pathophysiological consequences.
Alterations in these parameters by sulfhydryl-reactive
agents such as NAC are thought to be the primary mech-
anism for the improved mucus clearance for these agents.
We therefore examined the effects of the three drugs on
Figure 6 Effect of guaifenesin (GGE), N-acetylcysteine (NAC) or ambroxol (Amb) on mucociliary transport rates. Individual particle rates
for endogenous particles on the surface of human primary lung epithelial cell cultures are indicated by symbols. Lighter coloured symbols with
black borders indicate the 30 μM concentration of the drugs, while darker solid symbols indicate the 100 μM concentration of the drugs. Target
data collection was for at least 5 moving elements from each of three fields on each of 4 cultures. In some cases, insufficient numbers of particles
or fields with particles were found. Panels on the left side indicate the combined data from elements subjectively designated as individual
particles or those associated with mucus sheets. The middle panels show only those designated as individual particles and the panels on the
right show only those associated with mucus sheets. *, ** and *** indicate p < 0.05, 0.01 and 0.005, respectively, vs. the IL-13-only control
(ANOVA with Dunnett’s post-test). Horizontal lines above the groups indicate trend tests with p values < 0.05 (all include the IL-13-alone, zero
drug, condition as indicated by the short line over this bar at the same height).
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elasticity (G’) and viscosity (G”) moduli at 24 hr (Figure 7).
However, both GGE and NAC at either concentration
decreased both parameters by approximately one order of
magnitude. Amb was less effective, significantly decreasing
these parameters by 60–70% relative to the IL-13 group.
Few of the samples collected at 8 hr contained sufficient
material for analysis. Where sample quantities were suf-
ficient (control, IL-13-treated, 30 μM GGE, 100 μM
NAC and 100 μM Amb), the results were generally
consistent with the 24 hr results: GGE and NAC reduced
both G’ and G”, whereas Amb did not affect G’ and
increased G”.Discussion
In the present study, we found that IL-13 increased the
cellular content and secretion of MUC5AC and
decreased mucociliary transport. Interestingly, the cyto-
kine caused small decreases in both G’ and G”, which
were statistically significant. However, the changes were
less than 2-fold, and the biological significance of this
effect is probably minimal. None of the three mucoac-
tive agents were cytotoxic at the concentrations tested,
but they differed substantially in their properties. On-
ly NAC potently scavenged free radicals, while only
GGE had a concentration-dependent capacity to de-
crease the cellular content and secretion of MUC5AC.
Figure 7 Effects of guaifenesin (GGE), N-acetylcysteine (NAC) or ambroxol (Amb) on rheological parameters. G’ (elasticity) and G”
(viscosity) of the secretions from human primary lung epithelial cell cultures at 24 hr are shown. Elasticity and viscosity of collected, undiluted,
apical secretions were evaluated using a 20 mm parallel plate rheometer at a 50 μM gap size. ** and *** indicate p < 0.01 and 0.005, respectively,
vs. the IL-13-only control (ANOVA with Dunnett’s post-test).
Seagrave et al. Respiratory Research 2012, 13:98 Page 8 of 10
http://respiratory-research.com/content/13/1/98In contrast, all three drugs affected the rheology of the
secretions.
Mucolytics generally decrease mucus viscosity by re-
ducing the dicysteine bridges that contribute to the ri-
gidity of the mucins [16]. In the present study, NAC had
relatively small effects on the cellular content or secre-
tion of MUC5AC. However, it significantly decreased
the viscosity and elasticity parameters of the secretions.
Interestingly, NAC also appeared to reduce the total quan-
tity of endogenous debris and, in particular, the fraction
present as part of the mucus sheets. This aspect of the
regulation of mucociliary function may merit additional
study. Furthermore, 100 μM NAC decreased MTR for the
particles associated with mucus sheets to below those of
the IL-13-only cultures at all time points. It is possible this
resulted from strong effects on viscosity that disrupted ef-
fective coupling between the mucus and the beating cilia.
Amb is used clinically to improve cough and discomfort
from excessive mucus accumulation. Its mode of action is
not fully understood, but may include antioxidant, anti-
inflammatory or anaesthetic modes of action [11]. It also
may increase surfactant production [1] and alkaline phos-
phatase secretion (which is associated with surfactant, but
also reduces the effects of lipopolysaccharide) [17], and
alter ion transport [18]. In our studies, Amb suppressed
MUC5AC secretion and decreased MUC5AC cellular
content slightly, but the effect was not concentration-
dependent. Although this agent also altered the rheo-
logical parameters, the effect was substantially smaller
than that of either NAC or GGE.
Several hypotheses for the mechanisms of action for
GGE have been proposed. One suggested mechanism, the
neurogenic hypothesis, involves stimulation of receptors
in the stomach, resulting in vagal stimulation of respira-
tory tract fluid secretion, specifically cholinergic parasym-
pathetic reflexes activating submucosal gland secretions
[19]. There is also evidence for direct effects on mucus
adhesiveness and surface tension [20-22], and on cough
sensitivity [23]. Significant effects on mucociliary clearancehave also been demonstrated in chronic bronchitis
patients but not in healthy controls [20]. In contrast, no
direct effects on mucociliary clearance measured as sac-
charine transport time in vivo or ciliary beat frequency in
nasal epithelial cell samples isolated from GGE-treated
healthy volunteers were observed, although sampling arte-
facts in the isolation of the cells might have affected the
results [24]. In the present study, in contrast to the other
agents tested, GGE produced substantial concentration-
dependent decreases in both cellular MUC5AC content
and secretion in the IL-13-stimulated cultures, similar to
our previously reported results in unstimulated cells [8].
The effects on MUC5AC content and secretion were par-
alleled by increases in MTR and significant decreases in
both elasticity and viscosity parameters.
Added value in our study is provided by the correlations
among MUC5AC content and secretion, MTR and rhe-
ology, which support the concept that the drugs affect
selected parameters of the mucociliary transport system.
In addition, the use of endogenous materials to track the
MTR is an advantage. This method avoids potential dilu-
tion of the secretions and alterations in rheological prop-
erties that result when a suspension of exogenous particles
is added to the surfaces of the cultures. This study also
has some limitations. While the differentiated primary
human cell cultures are more realistic models of the air-
way than cell lines or conventionally cultured primary
cells, there is no actual clearance of the secretions, and the
cultures must be washed at intervals. For this reason, the
mucus levels vary from very little immediately after wash-
ing, to potentially large, depending on when the last
washes occurred. We attempted to standardise these pro-
cedures, but in order to ensure sufficient mucus for the
rheology measurements, the cultures for the MTR and
rheology measurements included mucus produced and
secreted during the 24 hr preceding drug treatment, while
the cultures used to assess MUC5AC content and secre-
tions were washed immediately prior to drug treatment.
We did not attempt to measure ciliary beat frequency or
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cells precludes evaluation of effects mediated by other
organs, such as the neurogenic mechanism postulated for
the early effects of GGE [19], which cannot be modelled
in lung cell cultures. Metabolism by hepatic enzymes is
also not included in the present model, and thus the time
course for in vivo responses may differ from those
observed in vitro. Finally, the contributions of mucins
other than MUC5AC were not addressed in this study.
These cultures exhibit modest numbers of MUC5AC-
producing goblet cells [5], which are increased by IL-13
treatment [10], but not fully differentiated submucosal
glands, the major source of MUC5B [6]. However,
MUC5B has been shown to be the major mucin in these
cultures [25]. It is, therefore, possible that the changes in
mucus properties are due to the presence of MUC5B in
the secretions. Future studies will address this possibility
directly.
Conclusions
In summary, this study indicates that GGE had a strong
inhibitory effect on the production of MUC5AC in IL-13-
stimulated cultures, which correlated with increased MTR
and reduced viscosity and elasticity of the secretions.
These effects were unlikely to have been the result of re-
duction of dicysteine bridges, given its lack of antioxidant
capacity. In contrast, NAC did not significantly affect the
cellular content or secretion of MUC5AC and had a bi-
phasic effect on MTR (increased at 30 μM but suppressed
at 100 μM, particularly for those particles associated with
the mucus sheets). As expected, NAC reduced the rheo-
logical parameters. Amb, like NAC, had no significant ef-
fect on the cellular content or secretion of MUC5AC, but
modestly increased MTR and reduced elasticity and vis-
cosity. Thus, we conclude that in human differentiated air-
way epithelial cells under conditions mimicking an
inflammatory response, GGE reduces MUC5AC produc-
tion, increases MTR, and decreases mucus viscosity and
elasticity. These results support the use of this drug for
hypersecretory conditions of the airways, including bacter-
ial or viral infections and chronic bronchitis.
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